



## European Patent Granted to RegenesiS Biomedical for Wound Care Device

*Establishes intellectual property rights on apparatus and method*

Scottsdale, Arizona, October 21, 2009 -- RegenesiS Biomedical, Inc., a medical technology company focused on regenerative medicine, announced today the European Patent Office has granted their patent *Improved Pulsed Electromagnetic Energy Treatment Apparatus and Method*.

The specific intellectual property protected relates to the marketed Provant Therapy system. It protects the unique process of therapeutic energy generation and patient treatment. The mention of the grant was published in the European Patent Bulletin on October 21, 2009.

“This patent grant protects the fundamental discoveries and development of the RegenesiS core technology,” said Virginia Rybski, President and CEO of RegenesiS Biomedical. “Our vision is to be a leader in tissue regenerative medicine.”

### About the Provant Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

### About RegenesiS Biomedical

RegenesiS Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. RegenesiS developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

*Contact:* RegenesiS Biomedical, Inc.  
Scott Robey, Vice President Marketing  
[www.regenesiSbio.com](http://www.regenesiSbio.com)  
480-970-4970 phone

SOURCE: RegenesiS Biomedical Inc.